TCL Archive Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer July 26, 2002
TCL Archive “Critical Issues” Include How U.S. NCI Spends Its Money. “Catastrophic” Cutback In Canada May 14, 1976
TCL Archive DCT Board Approves Concept Of Planning Grants For New Particle Therapy Equipment Development August 7, 1981
